Zymeworks (ZYME) Stock Forecast & Price Target $28.22 -0.22 (-0.77%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$27.44 -0.78 (-2.75%) As of 10/23/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Zymeworks - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 14 Analyst RatingsSell1Hold1Buy12 Based on 14 Wall Street analysts who have issued ratings for Zymeworks in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 1 has given a sell rating, 1 has given a hold rating, and 12 have given a buy rating for ZYME. Consensus Price Target $41.5847.35% Upside According to the 14 analysts' twelve-month price targets for Zymeworks, the average price target is $41.58. The highest price target for ZYME is $58.00, while the lowest price target for ZYME is $32.00. The average price target represents a forecasted upside of 47.35% from the current price of $28.22. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for ZYME and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Zymeworks and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZYME Analyst Ratings Over TimeTypeCurrent Forecast10/25/25 to 10/25/261 Month Ago9/25/25 to 9/25/263 Months Ago7/27/25 to 7/27/261 Year Ago10/25/24 to 10/25/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)1 Strong Buy rating(s)2 Strong Buy rating(s)Buy12 Buy rating(s)10 Buy rating(s)8 Buy rating(s)7 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)1 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$41.58$41.00$37.33$24.88Forecasted Upside47.35% Upside54.60% Upside62.32% Upside40.22% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy ZYME Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ZYME Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Zymeworks Stock vs. The CompetitionTypeZymeworksHealthcare CompaniesBroader MarketConsensus Rating Score 2.79 2.32 2.53Consensus RatingModerate BuyHoldModerate BuyPredicted Upside47.35% Upside1,400.11% Upside16.92% UpsideNews Sentiment RatingNeutral NewsSee Recent ZYME NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings Most Recent from Each Brokerage All Show All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action 10/25/2024 - 10/25/2026 Report Date Report Date From Report Date To 1M3M6MYTD1Y2Y3Y5Y More filters Fewer filters Done 0 Results Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/23/2026 Jefferies Financial Group3 of 5 stars Reiterated RatingBuy$52.00+84.46%10/15/2026 Weiss Ratings3 of 5 stars Reiterated RatingSell (D-)10/7/2026 Truist Financial2 of 5 starsGregory RenzaNot RatedBoost TargetBuy$32.00 ➝ $34.00+27.29%9/29/2026 CitigroupSubscribe to MarketBeat All Access to unlock brokerage rankingsYigal NochomovitzSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy$38.00 ➝ $39.00+43.81%9/29/2026 TD CowenSubscribe to MarketBeat All Access to unlock brokerage rankings Initiated CoverageBuy$34.00+24.20%9/17/2026 Wolfe ResearchSubscribe to MarketBeat All Access to unlock brokerage rankingsKalpit PatelSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOutperform9/3/2026 JPMorgan Chase & Co.Subscribe to MarketBeat All Access to unlock brokerage rankingsBrian ChengSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$31.00 ➝ $33.00+10.37%8/26/2026 Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access to unlock brokerage rankings Set Target$32.00+16.49%8/26/2026 Citizens JmpSubscribe to MarketBeat All Access to unlock brokerage rankingsReni BenjaminSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingMarket Outperform$32.00+16.49%8/26/2026 HC WainwrightSubscribe to MarketBeat All Access to unlock brokerage rankingsRobert BurnsSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetBuy$51.00 ➝ $55.00+100.22% Get the Latest News and Ratings for ZYME and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. 8/10/2026 B. Riley FinancialSubscribe to MarketBeat All Access to unlock brokerage rankingsMayank MamtaniSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy$40.00 ➝ $44.00+82.57%8/7/2026 Stifel NicolausSubscribe to MarketBeat All Access to unlock brokerage rankings Set Target$46.00+94.22%8/7/2026 Wells Fargo & CompanySubscribe to MarketBeat All Access to unlock brokerage rankingsEva Fortea-VerdejoSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$37.00 ➝ $40.00+72.94%3/3/2026 Leerink PartnersSubscribe to MarketBeat All Access to unlock brokerage rankingsAndrew BerensSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOutperform$52.00 ➝ $58.00+145.81%11/26/2025 Zacks ResearchSubscribe to MarketBeat All Access to unlock brokerage rankings DowngradeStrong-Buy ➝ Hold5/20/2025 TD SecuritiesSubscribe to MarketBeat All Access to unlock brokerage rankingsYaron WeberSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageBuy3/11/2025 Lifesci CapitalSubscribe to MarketBeat All Access to unlock brokerage rankingsCharles ZhuSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOutperform$30.00+170.27%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:04 PM ET. ZYME Forecast - Frequently Asked Questions What is Zymeworks' forecast for 2026? According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Zymeworks is $41.58, with a high forecast of $58.00 and a low forecast of $32.00. Should I buy or sell Zymeworks stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last twelve months. There is currently 1 sell rating, 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ZYME shares. Does Zymeworks's stock price have much upside? According to analysts, Zymeworks's stock has a predicted upside of 47.35% based on their 12-month stock forecasts. What analysts cover Zymeworks? Zymeworks has been rated by research analysts at B. Riley Financial, Citigroup, Citizens Jmp, Deutsche Bank Aktiengesellschaft, HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., Stifel Nicolaus, TD Cowen, Truist Financial, Weiss Ratings, Wells Fargo & Company, and Wolfe Research in the past 90 days. Do Wall Street analysts like Zymeworks more than its competitors? Analysts like Zymeworks more than other "healthcare" companies. The consensus rating for Zymeworks is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ZYME compares to other companies. Stock Forecasts and Research Tools Related Companies PRAX Stock Forecast ALKS Stock Forecast IOVA Stock Forecast KNSA Stock Forecast GRAL Stock Forecast RYTM Stock Forecast LGND Stock Forecast IMVT Stock Forecast KOD Stock Forecast CGON Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Zymeworks RecommendationsJefferies Financial GroupWeiss RatingsTruist FinancialCitigroupTD CowenWolfe ResearchJPMorgan Chase & Co.HC WainwrightCitizens JmpDeutsche Bank AktiengesellschaftB. Riley FinancialWells Fargo & CompanyStifel NicolausLeerink PartnersZacks Research MarketBeat monitors more than a dozen sources for Zymeworks analyst ratings, with the most recent rating issued on 10/23/2026. From Our PartnersWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.